[Federal Register: May 29, 2003 (Volume 68, Number 103)]
[Notices]               
[Page 32089]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr29my03-148]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Application

    Pursuant to section 1301.33(a) of title 21 of the Code of Federal 
Regulations (CFR), this is notice that on January 28, 2003, Roche 
Diagnostics Corporation, Attn: Regulatory Compliance, 9115 Hague Road, 
Indianapolis, Indiana 46250, made application by renewal and on January 
29, 2003, by letter to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of the basic classes of controlled 
substances listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lysergic Acid Diethylamide (7315)..........  I
Tetrahydrocannabinol (7370)................  I
Alphamethadol (9605).......................  I
Phencyclidine (7471).......................  II
Benzoylecogonine (9180)....................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
------------------------------------------------------------------------

    The firm plans to manufacture small quantities of controlled 
substances for use in diagnostic products.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office of chief Counsel (CCD) and must be filed no later than July 28, 
2003.

    Dated: May 2, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-13313 Filed 5-28-03; 8:45 am]

BILLING CODE 4410-09-M